EMPHYSEMATOUS CHOLECYSTITIS

This adverse event was reported 50 times

EMPHYSEMATOUS CHOLECYSTITIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 MEFENAMIC ACID 1 0.0005
1 AZACITIDINE 13 0.0004
2 INSULIN ASPART INJECTION 1 0.0004
3 FLUDARABINE PHOSPHATE 13 0.0003
4 FRUQUINTINIB 1 0.0003
5 HYDROCORTISONE SODIUM SUCCINATE 1 0.0003
6 VANCOMYCIN HYDROCHLORIDE 2 0.0002
7 CARMUSTINE 1 0.0002
8 VENETOCLAX 13 0.0002
9 RUXOLITINIB 13 0.0002
See all drugs enriched for association with EMPHYSEMATOUS CHOLECYSTITIS

EMPHYSEMATOUS CHOLECYSTITIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 BCL-2 Inhibitor [EPC] 13 0.0002
1 Tetracycline-class Antibacterial [EPC] 1 0.0001
2 Lipopeptide Antibacterial [EPC] 1 0.0001
3 Janus Kinase Inhibitor [EPC] 13 0.0001
4 GLP-2 Analog [EPC] 1 0.0001
5 Penem Antibacterial [EPC] 2 0.0001
6 Alkylating Drug [EPC] 14 0.0001
7 Nucleoside Metabolic Inhibitor [EPC] 13 0.0000
8 Bile Acid [EPC] 1 0.0000
9 CD20-directed Cytolytic Antibody [EPC] 13 0.0000
See all drug classes enriched for association with EMPHYSEMATOUS CHOLECYSTITIS